Conference Reports for NATAP

Back

17th CROI Conference on Retroviruses and Opportunistic Infections San Francisco, CA Feb 16-19, 2010     HIV Persistence, Raltegravir/Maravoric Intensification, Immunology: Some Impressions from San Francisco: CROI 2010 - written by David Margolis MD University of North Carolina - (03/23/10)   Management of Treatment-Experienced Patients: darunavir, raltegravir, raltegravir intensification, maraviroc, vicriviroc - written by Rafael E. Campo, MD Professor of Clinical Medicine Division of Infectious Diseases University of Miami Leonard M. Miller School of Medicine Miami, Florida - (03/23/10)   Clinical Pharmacology at CROI 2010: Advances in Antiretroviral Discovery, Drug Interactions, Compartmental Penetration, and Adverse Reactions - written by Courtney V. Fletcher, Pharm.D. Dean and Professor College of Pharmacy University of Nebraska Medical Center- (03/14/10)   Bone/Osteoporosis/Vitamin D CROI 2010 Update - written by Michael Yin, MD MS Assistant Professor of Clinical Medicine Columbia University Medical Center New York, NY- (03/14/10)   HIV Prevention at CROI 2010 - written by Jared Baeten, MD PhD Connie Celum, MD MPH University of Washington - (03/07/10)   Summary from CROI for Hepatitis Coinfection - What are the challenges and how can we improve management of Hepatitis coinfection in HIV-Infected Patients? - written by Jurgen K. Rockstroh M.D., Professor of Medicine University of Bonn, Germany - (03/03/10)   The Kidney at CROI - written by Christina M. Wyatt, MD Assistant Professor, Medicine/ Nephrology Mount Sinai School of Medicine New York, NY - (03/03/10)   Chronic Inflammation in HIV: CROI 2010 - written by David H Shepp, MD Associate Professor of Medicine, Hofstra University School of Medicine Division of Infectious Diseases, North Shore University Hospital-Manhasset - (03/03/10)   Metabolic complications of HIV infection at CROI 2010 (Feb 16-19) -Pablo Tebas, University of Pennsylvania. Philadelphia. (02/23/10)   A Finite Course of ART during Early HIV-1 Infection Modestly Delays Need for Subsequent ART Initiation: ACTG A5217, the SETPOINT Study - (06/12/10)   HAART Reduces New Infections - Decreases in Community Viral Load Are Associated with a Reduction in New HIV Diagnoses in San Francisco (CROI) - (04/05/10)   Prolonged Control of Viremia After Transfer of Autologous CD4 T Cells Genetically Modified with a Lentiviral Vector Expressing Long Antisense to HIV env (VRX496) - (04/04/10)   Antiviral and Immunological Effects of Intensification of Suppressive ART with Maraviroc, a CCR5 Antagonist - (03/22/10)   Antiviral and Immunological Effects of Intensification of Suppressive ART with Maraviroc, a CCR5 Antagonist - (03/22/10)   No Evolution of HIV-1 Total DNA and 2-LTR Circles after 48 Weeks of Raltegravir-containing Therapy in Patients with Controlled Viremia: A Sub-study of the Randomized EASIER-ANRS 138 Trial - (03/22/10)   Effect of the Intensification with a CCR5 Antagonist on the Decay of the HIV-1 Latent Reservoir and Residual Viremia - (03/22/10)   No Decrease in Intrathecal Immunoactivation or Residual CSF Viremiaduring Treatment Intensification in Patients on Stable ART - (03/22/10)   Quantification of Persistent Viremia in Cerebrospinal Fluid and Plasma: Initial Experience in a Raltegravir Intensification Study - (03/22/10)   Differences in HIV Burden throughout the Gut of Patients on Suppressive ART: Implications for HIV Persistence - (03/21/10)   HIV-1 Replication and Immune Dynamics Are Impacted by Raltegravir Intensification of HAART-suppressed Patients - (03/21/10)   Raltegravir Intensification in Antiretroviral-treated Patients Exhibiting a Suboptimal CD4+ T Cell Response - (03/21/10)   Efficacy of Intermittent Prophylaxis with Tenofovir and Emtricitabine against Rectal SHIV Transmission in Macaques and Relationship to Systemic and Mucosal Drug Levels - (03/19/10)   Protection of Rhesus Macaques from Vaginal Infection by Maraviroc (solution), an Inhibitor of HIV-1 Entry via the CCR5 Co-receptor - (03/19/10)   CROI: Inflammation/activation linked to diseases of organ systems (heart, kidney, liver) & death in USA and now reported as well in Africa - HIV accelerated aging will be bigger problem in undeveloped countries - (03/18/10)   INFLAMMATORY MARKERS DURING TREATMENT OF OIs ARE PREDICTIVE OF LATE VIROLOGIC AND IMMUNOLOGIC RESPONSES: Sub-study of A5164 - (03/16/10)   Prevalence of hypovitaminosis D among HIV+ patients enrolled in a large italian cohort - (03/15/10)   Longitudinal Analysis of Bone Mineral Density in Aging Men With or at Risk for HIV Infection: heroin causes bone loss; accelerated bone loss progressed over 3 years in HIV+ - (03/10/10)   Changes in Bone Mineral Density: two-years follow-up of the ANRS CO3 Aquitaine Cohort - Bone Metabolism Evolves- in 11% from osteopenia to osteoporosis and to osteopenia, bone markers worsen in 41% - (03/10/10)   HCV/HIV Co-infection Affects Neurocognitive Performance But Not Diffusion Tensor Imaging Measures - (03/10/10)   IL-28 Gene & HCV Recovery - (03/10/10)   Non-AIDS-defining Events among HAART-treated Adults in an Urban US vs an Urban Sub-Saharan African Setting: 'high non-AIDS events rate in Africa' - (03/09/10)   Low CD4 Cell Count and Impaired Renal Function (eGFR) Are Independent Risk Factors for ARF (acute renal failure) in HIV-infected Patients - (03/09/10)   Prevalence of Hepatitis Coinfection among HIV-Infected Nigerian Children in the Harvard PEPFAR ART Program - (03/09/10)   Persistent Low-level Viremia Is Associated with Increased Risk of Virologic Failure and Mortality - (03/09/10)   Association of IL28B Haplotypes with Chronic HCV Infection in HIV/HCV Co-infected Individuals - (03/09/10)   Genetic Variation in IL28B and Treatment-induced Clearance of HCV in HCV/HIV Co-infected Patients - (03/09/10)   Sustained Virological Response to Interferon plus Ribavirin Reduces HIV Progression and Non-liver-related Mortality in Patients Co-infected with HIV and HCV - (03/09/10)   Strong Association of a Single Nucleotide Polymorphism Located Near the Interleukin-28b Gene with Response to Hepatitis C Therapy in HIV/HCV Co-infected Patients - (03/07/10)   Incidence and Predictors of Anemia in HCV/HIV Co-infected Subjects Treated with Pegylated Interferon and Ribavirin in A5178 - (03/07/10)   All-cause Mortality in HIV-infected Patients in Spain Compared to the General Population according to HCV Status: HIV increases death risk 2.5 times, HCV coinfection increases death risk 11 times higher - (03/07/10)   Evaluation of the Anti-HCV Activity and Pharmacokinetics of ATI-0810, a Novel Inhibitor of HCV Replication - (03/07/10)   HCV Core Protein Induces Neuroinflammation and Potentiates HIV Vpr Neurotoxicity - (03/07/10)   Interleukin 28 B Genotype Is a Potent Predictor of Response to Therapy with Pegylated Interferon plus Ribavirin in HIV/HCV Co-infected Patients - (03/07/10)   Insulin Resistance Is a Major Predictor of Sustained Virological Response to Peginterferon and Ribavirin in HIV/HCV Co-infected Patients Undergoing HCV Retreatment - (03/07/10)   High Rate of Hepatitis C Infection Clearance in HIV-1 Natural Viral Suppressors - (03/07/10)   Fast Liver Damage Progression in HIV/HCV Co-infected Patients in Spite of Effective HAART - (03/07/10)   Impact of Zidovudine on Hematologic Parameters during Treatment with Peginterferon alfa-2a plus Ribavirin for Chronic Hepatitis C in HIV/HCV Co-infected Patients Enrolled in a Large Randomized Double-blind Study - (03/07/10)   Genetic Variability of the HCV NS3 Protease in HIV/HCV Co-infected Patients Treated with HIV Protease Inhibitors - (03/07/10)   Effect of Accompanying Antiretroviral Drugs on Virologic Response to PEG-IFN and Ribavirin in HIV/HCV Co-infected Patients: 'AZT not good, abacavir ok' - (03/07/10)   Biomarkers of Inflammation and Coagulation and Risk of Non-AIDS Death in HIV/Hepatitis Co-infected Patients in the SMART Study: inflammation associated with advanced liver disease - (03/07/10)   In the HAART Era, in Viral Cirrhosis Liver Transplant Candidates, HIV Co-infection Remains as an Independent Predictor of Mortality on the Waiting List with a death rate of 48% at 24 weeks), but Not after Liver Transplantation: - (03/07/10)   Survival of HIV-Infected Patients with Compensated Liver Cirrhosis: accelerated death rate; MELD & transient elastometry predict mortality - (03/07/10)   5-Year Tenofovir Therapy Is Associated with Maintained HBV Response and Renal Toxicity in HIV/HBV Co-infected Patients - (03/06/10)   Determinants of Incident Chronic Kidney Disease in a Cohort of HIV-infected Patients with Free Access to Care - (03/06/10)   Predictors for Change in Estimated Glomerular Filtration Rate in HIV-infected Individuals with or without cART: The Swiss HIV Cohort Study - (03/06/10)   Improved Correlation of Coronary Atherosclerosis with Estimated Glomerular Filtration Rate Assessed with Chronic Kidney Disease Epidemiology Collaboration Equation than with MDRD and Cockcroft-Gault in HIV-infected Patients - (03/06/10)   HAART Is Associated with Improved Kidney Function in Patients with Impaired Kidney Function at Baseline but Was Associated with Slight Worsening of Kidney Function in Patients with Normal Baseline Kidney Function - (03/06/10)   Chronic Renal Failure in HIV-Infected Patients: Incidence and Risk Factors (ANRS CO3 Aquitaine Cohort, France) - (03/06/10)   Episodes of HIV Viremia and the Risk of Non-AIDS Events among Successfully Treated Patients (503) - (03/06/10)   DNA Damage and p16-mediated Growth Arrest in HIV-1-specific CD8+ T Cells - (03/05/10)   Ritonavir and Lopinavir Boosted with Ritonavir Induce Endothelial dysfunction and Premature Senescence in Cultured Human Coronary Artery Endothelial Cells - (03/05/10)   In vitro Effect of CCR5 Antagonists on Innate Immune System: Maraviroc Inhibits the Migration of Neutrophils, Macrophages and Dendritic Cells - (03/05/10)   Vicriviroc Phase 3 at CROI 2010 - (03/05/10)   Plasma Levels of Soluble CD14 (activation marker) Predict Mortality in HIV Infection - (03/05/10)   Short-Term Raltegravir Monotherapy Does Not Predispose Patients to Develop RAL Resistance During Subsequent Combination Therapy: Analysis of Samples From Protocol 004 - (03/05/10)   Pharmacokinetic (PK), Safety and Efficacy Data on Cohort IIA; youth aged 6-11 from IMPAACT P1066: A Phase I/II Study to Evaluate Raltegravir (RAL) in HIV-1 Infected Youth - (03/05/10)   Maraviroc Fully Inhibits Dual-R5 Virus in Dual/Mixed HIV-1 Infected Patient - (03/04/10)   Hepatic Safety & Efficacy of Raltegravir in Patients Co-infected with HIV and Hepatitis B (HBV) and/or C (HCV) Virus - (03/04/10)   A Pharmacokinetic Comparison of Adult and Pediatric Formulations of Raltegravir (RAL) in Healthy Adults - (03/04/10)   Screening for Hepatocellular Carcinoma (HCC) in HIV/HCV-Coinfected Patients: Impact on Staging, Therapy, and Survival - (03/04/10)   Resistance Associated Mutations to Etravirine (TMC-125) in Antiretroviral Naïve Patients infected with non-B HIV-1 subtypes - (03/04/10)   Determining HIV-1 Coreceptor Tropism Using PBMC Proviral DNA Derived from Aviremic Blood Samples, for Patients with Undetectable Viral Load - (03/04/10)   The Prevalence of Darunavir Associated Mutations in PI-naive and PI-experienced HIV-1 Infected Children in the UK - (03/04/10)   Maraviroc Fully Inhibits Dual-R5 Virus in Dual/Mixed HIV-1 Infected Patients - (03/04/10)   Effect of the Intensification with a CCR5 Antagonist Maraviroc on the Decay of the HIV-1 Latent Reservoir and Residual Viremia - reduced activation - (03/04/10)   Effect of CCL3L1 Copy Number Variation on CD4+ Cell Recovery in Treatment-Naïve Patients: 96-Week Results from the Maraviroc in Treatment-Naïve Patients (MERIT) Study - (03/04/10)   Genotypic Analysis of the HIV-1 gp120 V3 Loop for Treatment-Experienced Patients Enrolled Into the MOTIVATE Studies and Who Received Maraviroc + Optimized Background Therapy - (03/03/10)   Population-based Sequencing of the V3-loop is Comparable to the Enhanced Sensitivity Trofile Assay (ESTA) in Predicting Virologic Response to Maraviroc of Treatment-naïve Patients in the MERIT Trial - (03/03/10)   Mechanisms of Virologic Failure With Maraviroc in Treatment-Naïve HIV-1-Infected Patients Through 96 Weeks - (03/03/10)   Large-Scale Application of "Deep" Sequencing Using 454 Technology to HIV Tropism Screening - (03/03/10)   HIV Did Not Worsen H1N1 Severity in Spanish Case-Control Study - written by Mark Mascolini - (03/03/10)   Failure to Respond to HBV Vaccine Linked to Higher Cancer Risk With HIV - written by Mark Mascolini - (03/03/10)   Prediction of X4-tropic Human Immunodeficiency Virus from Proviral Envelope Sequence in Patients with Suppressed Viral Load on Antiretroviral Therapy (ART). - (03/03/10)   Four Non-AIDS Cancers on the Rise With HIV in Big North American Cohort - written by Mark Mascolini - (03/03/10)   Correlation of Inflammatory Biomarkers with the Framingham Coronary Risk Score in Antiretroviral-naïve HIV-1 Infected Patients - (03/03/10)   Trends in Cumulative Incidence of Cancer among HIV-infected Patients in North America: high cancer rates in HIV+ - (03/03/10)   Prevalence (59%) and Correlates of Minor Neurocognitive Disorders in Asymptomatic HIV-infected Outpatients - (03/03/10)   Modest Lipid and Body Fat Changes With Raltegravir vs Efavirenz in 96-Week Trial - written by Mark Mascolini - - (03/02/10)   CDC Finds 1 in 6 Newly Diagnosed With HIV Had Resistant Virus in 2007 - written by Mark Mascolini - - (03/02/10)   Chronic Kidney Disease and Exposure to ART in a Large Cohort with Long-term Follow-up: The EuroSIDA Study - abstract 107LB - (03/02/10)   Higher Levels of Heart Cell Peptide Tied to Cardiovascular Disease in SMART Study Patients - written by Mark Mascolini - (03/01/10)   D-Dimer But Not hsCRP Predicts Impending Cardiovascular Disease in Case-Control Study - written by Mark Mascolini - (03/01/10)   Antiretrovirals for Prevention: Maraviroc Exposure in the Semen and Rectal Tissue of Healthy Male Volunteers after Single and Multiple Dosing - (03/01/10)   Risk of Non-AIDS Death in HIV/HCV-Coinfected People in SMART - written by Mark Mascolini - (03/01/10)   T cell Senescence and Proliferation Defects Persist in Treated HIV-infected Individuals Maintaining Viral Suppression and Are Associated with Poor CD4+ T Cell Recovery - (03/01/10)   Impact of CD8+ T Cell Activation on CD4+ T Cell Recovery and Mortality in HIV-infected Ugandans Initiating Antiretroviral Therapy - (03/01/10)   Valganciclovir Reduces CD8+ T Cell Activation among HIV-infected Patients with Suboptimal CD4+ T cell Recovery During Antiretroviral Therapy - (03/01/10)   CD4 at HAART Initiation Predicts Long Term CD4 Responses and Mortality from AIDS and non-AIDS Causes in the HIV Outpatient Study (HOPS) - (03/01/10)   Improved Genotypic Algorithm for Predicting Etravirine Susceptibility: Comprehensive List of Mutations Identified Through Correlation with Matched Phenotype - (03/01/10)   Lack of Interaction between Etravirine and Raltegravir plus Darunavir/Ritonavir when Combined in Treatment Experienced Patients: a Substudy of the ANRS 139 TRIO Trial - (03/01/10)   Antiretrovirals for Prevention: Maraviroc Exposure in the Semen and Rectal Tissue of Healthy Male Volunteers after Single and Multiple Dosing - (03/01/10)   Antiretrovirals For Prevention: tenofovir, FTC, maraviroc; rectal, vaginal, semen. - (03/01/10)   Maraviroc Fully Inhibits Dual-R5 Virus in Dual/Mixed HIV-1 Infected Patients - (03/01/10)   Effect of Raltegravir-containing Intensification on HIV burden and T cell Activation in the Gut of HIV+ Adults on Suppressive Antiretroviral Therapy (ART) - reduced activation - (03/01/10)   Nadir CD4 Count Under 350 Predicts Arterial Stiffness in Case-Control Study - written by Mark Mascolini - (02/28/10)   Sociobehavioral Factors Affect Clinical Outcomes Apart From HIV Factors in Swiss Cohort - written by Mark Mascolini - (02/28/10)   Darunavir Penetrates Semen Well With High Levels Through 24 Hours - written by Mark Mascolini - (02/28/10)   Darunavir Concentrations in Seminal Plasma in patients receiving Darunavir/ritonavir(DRV/r) monotherapy: a MONOI-ANRS 136 substudy - (02/28/10)   Darunavir Monotherapy Increased Limb Fat - Fat Tissue Distribution Changes in HIV-infected Patients with Viral Suppression Treated with Darunavir/ritonavir (DRV/r) monotherapy versus 2 NRTIs + DRV/r in the MONOI-ANRS 136 Randomized Trial : Results at 48 weeks - (02/28/10)   Maraviroc Levels in Cerebrospinal Fluid (CSF) and Seminal Plasma from HIV-Infected Patients - (02/28/10)   Correlates of Time-to-Loss-of-Viral-Response in CSF and Plasma in the CHARTER Cohort: CPE Score predicts CSF suppression - (02/27/10)   Neuropsychological Performance is Better in HIV-Infected Subjects Treated with Neuroactive HAART (02/27/10)   Plasma HIV Load Strongest Predictor of CSF Load in CHARTER Cohort - written by Mark Mascolini - (02/26/10)   Early Initiation of Antiretroviral Therapy in HIV-Infected Individuals Is Associated with Reduced Arterial Stiffness: a low nadir CD4+ T-cell counts are associated with arterial stiffness as assessed by Aix and PWV - (02/26/10)   Inflammation Is Associated with Endothelial Dysfunction Among Individuals with Treated and Suppressed HIV Infection - (02/26/10)   High Prevalence of Severe Vitamin D Deficiency in cART Naïve and Successfully Treated Swiss HIV Patients - (02/26/10)   Vitamin D Deficiency and Bacterial Vaginosis among HIV-infected and -uninfected Women in the United States - (02/26/10)   Assessment of Vitamin D Levels Among HIV-infected Persons in the Study To Understand the Natural History of HIV/AIDS in the Era of Effective Therapy (SUN Study) - (02/26/10)   The Discovery of S/GSK1349572: A Once Daily Next Generation Integrase Inhibitor with a Superior Resistance Profile - (02/25/10)   Positive HBV Vaccine Response Halves HIV Progression and Death Risk in US Military - written by Mark Mascolini - (02/25/10)   Cell Studies Point to Antiinflammatory Activity of Maraviroc - written by Mark Mascolini - (02/25/10)   Elvucitabine Versus 3TC in First-Line Regimens for 96 Weeks - see slides from poster below - written by Mark Mascolini - (02/25/10)   Early Antiretrovirals in People Diagnosed With AIDS May Quell Inflammation Faster - written by Mark Mascolini - (02/25/10)   The US Epidemic - Disparities in HIV Disease for African-Americans (02/25/10)   Maraviroc (MVC) Intensification for Suboptimal CD4+ Response Despite Sustained Virologic Suppression: ACTG 5256 (02/25/10)   CNS Toxicity of Antiretroviral Drugs (02/25/10)   Inflammation and Mortality in HIV-infected Adults: Analysis of the FRAM Study Cohort (02/25/10)   Effect of Atazanavir and Atazanavir/Ritonavir on the Pharmacokinetics of the Next Generation Integrase Inhibitor, S/GSK1349572 (02/25/10)   S/GSK1349572 is a Potent Next Generation HIV Integrase Inhibitor and Demonstrates a Superior Resistance Profile Substantiated with 60 Integrase Mutant Molecular Clones (02/23/10)   Worse Neuropsych Scores Tied to Viral Rebounds in CSF and Plasma; CPE Score Tied to CSF Rebound - written by Mark Mascolini - (02/23/10)   Low CD4 Nadir Predicts Neurocognitive Problems Despite Good CD4 Gains - written by Mark Mascolini - (02/23/10)   Standard First Regimens Less Effective in US Blacks Than Others - written by Mark Mascolini - (02/23/10)   ART Improves Cerebral Blood Flow--But Not to Levels in HIV-Negatives - written by Mark Mascolini - (02/23/10)   Bone & Limb Fat Outcomes in ACTG5202- More Bone Loss With TDF/FTC Than ABC/3TC - written by Mark Mascolini - (02/23/10)   Bone Fractures at CROI 2010 - see slides below - (02/23/10)   Elevated Cancer Risks Remains in HAART Era: increasing mortality risk due to non-AIDS cancers- increased risk for these no-AIDS cancers - anal, liver, Hodgkin lymphoma, lung - (02/23/10)   Recent CD4 Predicts Risk for Cancers; Increased Risk for Anal/liver/Hodgkin Lymphoma/oral cavity pharynx cancers in HIV+ - (02/23/10)   Mixed Findings on Value of Brain-Penetrating Antiretroviral Scores - written by Mark Mascolini - (02/22/10)   Bone Disease: Risk Factors - (02/22/10)   Raltegravir Concentrations in the Cervicovaginal Compartment Exceed the Median Inhibitory Concentration in HIV-1-infected Women Treated with a Raltegravir-containing Regimen: DIVA 01 Study - (02/22/10)   Sustained Antiretroviral Efficacy of Raltegravir after 192 Weeks of Combination ART in Treatment-Naive HIV-1 Infected Patients - (02/22/10)   Rapid Progression of Atherosclerosis at the Carotid Bifurcation Is Linked to Inflammation in HIV-infected Patients - "These data strongly suggest that inflammation contributes to the higher risk of atherosclerosis noted in HIV-infected persons." - (02/22/10)   CROI (2010 Feb 16-19) Selected Neurocognitive Abstracts - (02/22/10)   Vitamin D Deficiency Prevalence and Associations - (02/22/10)   A 48 week randomized study of uridine supplementation versus switch to tenofovir on limb fat, mitochondrial function, inflammation, and bone mineral density in HIV lipoatrophy - (02/22/10)   Uridine supplementation in the management of HIV lipoatrophy: Results of ACTG 5229 - (02/22/10)   Safety and Efficacy of TBR-652, a Chemokine Receptor 5 (CCR5) Antagonist, in HIV-1-Infected, Antiretroviral (ARV) Treatment-Experienced, CCR5 Antagonist-Naïve Patients - (02/22/10)   Discovery of Potent HIV-1 Capsid Assembly Inhibitors - (02/22/10)   T-cell Senescence and T-cell Activation Predict Carotid Atherosclerosis in HIV-infected Women - (02/22/10)   T-Cell Activation and Senescence Linked to Carotid Lesions in HIV+ Women - written by Mark Mascolini - (02/21/10)   Heart Risk Factors Tied to Neurocognitive Skills in SMART Substudy - written by Mark Mascolini - (02/21/10)   Baseline Liver Disease is Independently Associated with Risk of Death among HIV/HCV co-infected Adults with Histologic Staging - (02/20/10)   Interim Results from IMPAACT P1066: Raltegravir (RAL) Oral Chewable Tablet (OCT) Formulation in Children 6-11 Years - (02/20/10)   High Triglycerides Independently Raise MI Risk in DAD Study - written by Mark Mascolini - (02/20/10)   Three Years With More Than 500 CD4s Normalizes Mortality in HIV+ Men - written by Mark Mascolini - (02/20/10)   Life Expectancy Approaches Normal in Dutch Without HIV Symptoms - written by Mark Mascolini - (02/20/10)   Chronic HIV and HCV Swell Stroke Risk in Veterans Aging Cohort - written by Mark Mascolini - (02/20/10)   Fast ART in Late Disease Means Slower Progression in Europe and Canada - written by Mark Mascolini - (02/20/10)   Heart Risk Falls With Time Since Quitting Smoking in DAD - written by Mark Mascolini - (02/20/10)   Metabolic Profiles and Body Composition Changes in Treatment-Naïve HIV-Infected Patients Treated with Raltegravir 400 mg bid-based vs. Efavirenz 600 mg qhs-based Combination Therapy: 96-Week Follow-Up - (02/20/10)   Chronic kidney disease and exposure to ARTs in a large cohrt with long-term follow-up: EuroSida - (02/20/10)   Bone & Limb Fat Outcomes in ACTG5202 Substudy: abacavir/3TC, tenofivir/FTC, efavirenz, atazanavir/r - (02/20/10)   Inflammation and Fibrosis Markers Tied to AIDS or Death After Good Virologic Response - written by Mark Mascolini - (02/19/10)   Inflammation Tied to Endothelial Dysfunction Despite Tight HIV Control - written by Mark Mascolini - (02/19/10)   Antiretroviral Risk Factors for Kidney Disease in EuroSIDA: Tenofovir Is Not Alone - written by Mark Mascolini - (02/19/10)   Most Non-AIDS Cancers Not Diagnosed at Earlier Age in People With AIDS - written by Mark Mascolini - (02/19/10)   HIV Load Tied to Fibrosis Signal in Women Without Hepatitis or Alcohol Abuse - written by Mark Mascolini - (02/19/10)   QUAD Four-in-One Pill as Strong as Atripla, But a Kidney Concern Arises - written by Mark Mascolini - (02/18/10)   Maraviroc Does Not Boost Stalled CD4s in Virologically Suppressed People - written by Mark Mascolini - (02/18/10)   Vicriviroc Does Not Outdo Placebo Regimen in Phase 3 Trials - written by Mark Mascolini - (02/18/10)   Older Age, Lower CD4 Nadir, NNRTI Use Predict Slow CD4 Recovery in ATHENA - written by Mark Mascolini - (02/18/10)   High Rate of Coronary Artery Problems in Young People Tied to TDF/FTC - written by Mark Mascolini - (02/18/10)   Low-Level Viremia Quadruples Death Risk in Canadian Cohort Study - written by Mark Mascolini - (02/18/10)   Side Effect and CD4 Differences in Four ACTG 5202 Arms at 96 Weeks - written by Mark Mascolini - (02/18/10)   RNA Spikes Predict Heart Disease, CD4s Predict Liver and Kidney Disease - written by Mark Mascolini - (02/18/10)   ODIN: efficacy and safety at 48 weeks of once-daily versus twice-daily darunavir/ritonavir in treatment-experienced HIV-1-infected patients with no darunavir resistance-associated mutations - (02/18/10)   Bristol-Myers Squibb Media Statement on ACTG 5202 - (02/18/10)   ACTG5202 - (02/18/10)   New Data on ISENTRESS (raltegravir) Presented at the Conference on Retroviruses and Opportunistic Infections (CROI) - Merck announcement - (02/18/10)   The Single-Tablet, Fixed-Dose Regimen of Elvitegravir/GS-9350/Emtricitabine/Tenofovir DF (Quad) Achieves a High Rate of Virologic Suppression and GS-9350 is an Effective Booster - (02/18/10)